Suppr超能文献

去甲基化诱导 Shc3 过表达驱动 HCC 中 c-Raf 非依赖性的 MEK/ERK 激活。

Demethylation-Induced Overexpression of Shc3 Drives c-Raf-Independent Activation of MEK/ERK in HCC.

机构信息

Key Laboratory of Breast Cancer Prevention and Therapy, Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.

Department of Hepatic Biliary Pancreatic Surgery, Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan Province, China.

出版信息

Cancer Res. 2018 May 1;78(9):2219-2232. doi: 10.1158/0008-5472.CAN-17-2432. Epub 2018 Jan 12.

Abstract

Invasion and intrahepatic metastasis are major factors of poor prognosis in patients with hepatocellular carcinoma (HCC). In this study, we show that increased Src homolog and collagen homolog 3 (Shc3) expression in malignant HCC cell lines associate with HCC invasion and metastasis. Shc3 (N-Shc) was significantly upregulated in tumors of 33 HCC patient samples as compared with adjacent normal tissues. Further analysis of 52 HCC patient samples showed that Shc3 expression correlated with microvascular invasion, cancer staging, and poor prognosis. Shc3 interacted with major vault protein, resulting in activation of MEK1/2 and ERK1/2 independently of Shc1 and c-Raf; this interaction consequently induced epithelial-mesenchymal transition and promoted HCC cell proliferation and metastasis. The observed increase in Shc3 levels was due to demethylation of its upstream promoter, which allowed c-Jun binding. In turn, Shc3 expression promoted c-Jun phosphorylation in a positive feedback loop. Analysis of metastasis using a tumor xenograft mouse model further confirmed the role of Shc3 Taken together, our results indicate the importance of Shc3 in HCC progression and identify Shc3 as a novel biomarker and potential therapeutic target in HCC. Ectopic expression of Shc3 forms a complex with MVP/MEK/ERK to potentiate ERK activation and plays an important role in sorafinib resistance in HCC. .

摘要

在肝细胞癌(HCC)患者中,侵袭和肝内转移是预后不良的主要因素。在这项研究中,我们表明,恶性 HCC 细胞系中Src 同源物和胶原蛋白同源物 3(Shc3)表达的增加与 HCC 的侵袭和转移有关。与相邻正常组织相比,在 33 例 HCC 患者样本的肿瘤中,Shc3(N-Shc)显著上调。对 52 例 HCC 患者样本的进一步分析表明,Shc3 的表达与微血管侵犯、癌症分期和预后不良相关。Shc3 与主要穹窿蛋白相互作用,导致 MEK1/2 和 ERK1/2 的激活独立于 Shc1 和 c-Raf;这种相互作用继而诱导上皮-间充质转化,并促进 HCC 细胞增殖和转移。Shc3 水平的升高是由于其上游启动子的去甲基化,从而允许 c-Jun 结合。反过来,Shc3 的表达在正反馈环中促进 c-Jun 的磷酸化。使用肿瘤异种移植小鼠模型进行的转移分析进一步证实了 Shc3 的作用。

综上所述,我们的研究结果表明 Shc3 在 HCC 进展中的重要性,并将 Shc3 鉴定为 HCC 中的一种新的生物标志物和潜在治疗靶点。Shc3 的异位表达与 MVP/MEK/ERK 形成复合物,增强 ERK 激活,并在 HCC 对索拉非尼的耐药性中发挥重要作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验